Chembond Material Technologies Limited (CHEMBOND) Fair Value & Analysis
Basic Materials · IN · Market cap ₹2.5B
Fair value as of: Jun 29, 2026
Analysis
Chembond Material Technologies Limited (CHEMBOND) currently trades at ₹184.00, while our model-based Fair Value estimate is ₹143.46 — implying the stock looks roughly 22.0% overvalued today. We read business quality at 97/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Chembond Material Technologies Limited manufactures, sells, and trades specialty chemicals in India and internationally. It offers polymers, construction chemicals, high performance coatings, animal nutrition's, and industrial biotech products. The company also provides specialty chemicals, vitamins and minerals, probiotic, and prebiotic enzymes, as well as feed additives and nutrition products related to animal health. It is involved in water technologies, construction chemicals, industrial cleaning and hygiene, and distribution business. Chembond Material Technologies Limited was formerly known as Chembond Chemicals Limited and changed its name to Chembond Material Technologies Limited in May 2025. The company was founded in 1973 and is based in Navi Mumbai, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Chembond Material Technologies Limited (CHEMBOND) undervalued?
What is the fair value of CHEMBOND?
What is the quality score of CHEMBOND?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.